Breast and ovarian cancers from BRCA2-heterozygous patients often develop TP53 mutations [10]–[12], which may precede loss of the wildtype BRCA2 allele [13], and are not attributable to a generalized or random increase in genetic mutations [10]. This evidence concerns the gene BRCA2 and ovarian cancer.